Trial Profile

Observational, multicenter, open-label REFLECT study of Sandoz rituximab (GP2013; SDZ-RTX) for the treatment of diffuse large B-cell lymphoma

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 13 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
Indications Diffuse large B cell lymphoma
Focus Therapeutic Use
Acronyms REFLECT

Most Recent Events

17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association
17 Jun 2022 Status changed to completed as per results presented at the 27th Congress of the European Haematology Association
21 Jun 2020 Interim results (data cut off 30 Sep 2019, n=170) evaluating the efficacy and safety of SDZ-RTX for the treatment of diffuse large B-cell lymphoma, presented at the 25th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com